Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

Delayed Quote. Delayed  - 04/29 09:59:59 pm
33.35 USD   -2.40%
04/19 IMPAX LABORATOR : AmerisourceBergen unit recall more than 35M fenofi..
04/18 IMPAX LABORATOR : to Report First Quarter 2016 Results on May 10, 20..
04/14 IMPAX LABORATOR : Announces the Retirement of Nigel Ten Fleming, Ph...
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2013 | 01:35pm CEST

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on IMPAX LABORATORIES INC
04/28 IMPAX LABORATORIES : to Report First Quarter 2016 Results on May 10, 2016
04/21 IMPAX LABORATORIES : Announces Availability of EMVERM mebendazole Chewable Table..
04/21 IMPAX LABORATORIES : Announces the Retirement of Nigel Ten Fleming, Ph.D. and Mi..
04/19 IMPAX LABORATORIES : AmerisourceBergen unit recall more than 35M fenofibrate cap..
04/18 IMPAX LABORATORIES : to Report First Quarter 2016 Results on May 10, 2016
04/14 IMPAX LABORATORIES : Announces the Retirement of Nigel Ten Fleming, Ph.D. and Mi..
04/14 IMPAX LABORATORIES : Announces the Retirement of Nigel Ten Fleming, Ph.D. and Mi..
04/13 IMPAX LABORATORIES : Announces Availability of EMVERM™ (mebendazole) Chewa..
04/08 IMPAX ASSET MANAGEMENT : Boosted By US Segregated Account Win
04/01 IMPAX LABORATORIES : FTC sues Endo Pharma over pay-to-delay deals
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials